Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on May 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 411,750 shares of common stock to 27 new employees.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $14.51, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and plans to commercialize DIFICID™ (fidaxomicin) tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). CDAD is associated with a bacterial infection that is estimated to affect 700,000 people each year in the U.S. alone, and has surpassed MRSA as the leading cause of healthcare-acquired infections in community hospitals. Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
John D. Prunty, Chief Financial Officer & Senior Vice President, Finance
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
2. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
3. Optimer Pharmaceuticals Expands Senior Management Team
4. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
5. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
6. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
7. Trading Halted Today in Optimer Pharmaceuticals Stock
8. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
9. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
10. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
11. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Sweden , March 22, 2017 TFS ... and Mr. Ed Tumaian , two global executive positions ... will be joining the Operational Leadership Team and will report to ... ... comes to TFS with 10 years of medical and scientific ...
(Date:3/22/2017)... N.Y. , March 22, 2017  As the ... Leukemia & Lymphoma Society (LLS) has played a role ... patients, some of which are even helping patients with ... due to LLS,s significant investment in cutting-edge research – ... milestone continues to grow with the record-breaking sum of ...
(Date:3/22/2017)... -- NetworkNewsWire Editorial Coverage  ... Deciphering marijuana policy under the ... House officials. Federal laws are at odds with a number ... use, and businesses like SinglePoint, Inc. (OTC: SING) ( SING ... Inc. (OTC: MJNA), Cannabis Science, Inc. (OTC: CBIS) and ChineseInvestors.com, ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Old School Labs™, makers of the ... as a new Brand Ambassador. Theophane, who trained with Floyd Mayweather, made his professional ... He has racked up an impressive number of wins in contests in Britain, Germany ...
(Date:3/22/2017)... ... March 22, 2017 , ... Influence ... its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric teaching ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... a research collaboration to translate advances in basic neuroscience at the BMRI labs ... beyond. The collaboration seeks to improve movement, vision, and cognition impaired by stroke, traumatic ...
(Date:3/22/2017)... NY (PRWEB) , ... March 22, 2017 , ... The ... communities in the greater Nassau County region, is embarking on a combined charity effort ... cancer. , For the last 25 years, the Great Neck Breast Cancer Coalition ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Chris Humphrey ... to families and business professionals throughout the coastal plains region, is initiating a charity ... overcome cancer. , Dillyn was first diagnosed with leukemia on a Friday evening in ...
Breaking Medicine News(10 mins):